Emergent BioSolutions Inc
EBS
Company Profile
Business description
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Contact
300 Professional Drive
GaithersburgMD20879
USAT: +1 240 631-3200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
900
Stocks News & Analysis
stocks
WiseTech result disappoints, but the future looks bright
Markets appear underwhelmed by recent sales growth, however, our kingmaker thesis is intact.
stocks
WOW earnings: Woolworths losing market share, but will catch up to Coles
Woolworths have had a soft start to a challenging year, but Morningstar analyst believes it will eventually catch up to its main competitor.
stocks
Chart of the Week: Largest share price falls during earnings
Opportunities arise when the market overreacts, and good quality companies are mispriced.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,241.10 | 0.50 | -0.01% |
| CAC 40 | 7,762.60 | 18.67 | 0.24% |
| DAX 40 | 24,039.92 | 6.29 | -0.03% |
| Dow JONES (US) | 45,573.14 | 7.91 | 0.02% |
| FTSE 100 | 9,216.82 | 38.68 | -0.42% |
| HKSE | 24,998.82 | 202.94 | -0.81% |
| NASDAQ | 21,700.56 | 110.42 | 0.51% |
| Nikkei 225 | 42,828.79 | 308.52 | 0.73% |
| NZX 50 Index | 12,903.08 | 41.24 | 0.32% |
| S&P 500 | 6,495.76 | 14.36 | 0.22% |
| S&P/ASX 200 | 8,980.00 | 9.50 | 0.11% |
| SSE Composite Index | 3,843.60 | 43.25 | 1.14% |